November is Gastric Cancer Awareness Month.

This month and beyond, Jazz Pharmaceuticals is committed to treatment innovation for patients with gastric cancer. Together, we're working toward a brighter future.

Gastric cancer is the 5th most commonly diagnosed type of cancer globally, with over 30,000 people diagnosed in the United States each year.1,2

Gastric Cancer Awareness Month gives us a chance to recognize how treatment decisions depend on each patient's particular needs. Understanding biomarkers can help you treat patient populations according to their specific disease characteristics. Knowing how biomarkers like HER2 can impact the treatment landscape can help you make individualized treatment decisions that may benefit your patients.

~14%

of gastric cancer patients have HER2 overexpression, which can inform appropriate treatment options.3

In advanced gastric cancer, timely and comprehensive biomarker testing is more than just a diagnostic step. Identifying HER2-positive disease at diagnosis allows us to incorporate HER2-directed therapies that can meaningfully extend patients' lives. The right treatment, guided by the right biomarker, at the right time can make a life-changing difference.
— Dr Darshil Shah, Ironwood Cancer Research Centers, Scottsdale, AZ
Gastric cancer is a hard diagnosis, but it is no longer a field standing still. Biomarker testing, especially for HER2, helps us match patients to treatments built around their disease. As a clinician-researcher, I see new drugs and new trials giving my patients more options than ever, and that is what I hold on to when I talk with them about hope.
— Dr Rutika Mehta, Director, Upper GI Program, NYU Langone Health, Perlmutter Cancer Center, New York, NY

HER2 testing at the time of an advanced gastric cancer diagnosis is a critical step in determining whether targeted treatment may be appropriate.4-6

For patients with gastric cancer, tailoring treatment to biomarker status can impact outcomes, but

~40%

of patients with HER2+ advanced gastric or esophageal cancer do not receive 1L therapy with a HER2-targeted treatment regimen.7

Learn how Jazz's HER2-targeted treatment option can help your gastric cancer patients

Explore this treatment option

Jazz Pharmaceuticals is deeply committed to advancing care and supporting the gastric cancer patient community. We are proud to raise awareness this November and beyond, always pushing for a brighter future for people living with gastric cancer.

Your patients shouldn't have to navigate their gastric cancer journeys alone. Jazz Pharmaceuticals has put together a list of resources for your patients, including support groups and organizations offering advice for their day-to-day lives.

View advocacy resources to help your patients find support

View resources

1L=first-line; HER2=human epidermal growth factor receptor 2.

References:

  1. Stomach (Gastric) Cancer key statistics. American Cancer Society. https://www.cancer.org/cancer/types/stomach-cancer/key-statistics.html. Published February 27, 2026.
  2. Ilic M, Ilic I. Epidemiology of stomach cancer. World J Gastroenterol. 2022;28(12):1187-1203. doi:10.3748/wjg.v28.i12.1187
  3. Mehta R, Liepa AM, Zheng S, Chatterjee A. Real-World Molecular Biomarker testing patterns and results for advanced gastroesophageal cancers in the United States. Curr Oncol. 2023;30(2):1869-1881. doi:10.3390/curroncol30020145.
  4. Orillard E, Henriques J, Vernerey D, et al. Interest of the addition of taxanes to standard treatment in first-line advanced HER2 positive gastroesophageal adenocarcinoma in selective patients. Front Oncol. 2022;12:763926. doi:10.3389/fonc.2022.763926
  5. Sepulveda AR, Hamilton SR, Allegra CJ, et al. Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. J Clin Oncol. 2017;35(13):1453-1486. doi:10.1200/jco.2016.71.9807
  6. Rüschoff J, Hanna W, Bilous M, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012;25(5):637-650. doi:10.1038/modpathol.2011.198
  7. Dayyani F, Fan X, Zape J, et al. Real-world treatment patterns and overall survival in patients with HER2-positive advanced or metastatic gastroesophageal adenocarcinomas in the US. Presented at: American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2026; Chicago, IL.